UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 15, 2006
FAVRILLE, INC.
(Exact Name of Registrant as Specified in Charter)
DELAWARE | 000-51134 | 33-0892797 |
(State or Other Jurisdiction | (Commission File Number) | (I.R.S. Employer |
of Incorporation) | | Identification No.) |
| | |
| 10421 PACIFIC CENTER COURT | |
| SAN DIEGO, CALIFORNIA | 92121 |
| (Address of Principal Executive Offices) | (Zip Code) |
(858) 526-8000
(Registrants telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CRF 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On June 15, 2006, Favrille issued a press release announcing that the Company’s electronic Investigational New Drug application for FAV-201, a patient-specific immunotherapy for the treatment of T-cell lymphoma, has been cleared by the U.S. Food & Drug Administration. Initially, FAV-201 will be evaluated in cutaneous T-cell lymphoma. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
99.1 Press release of the registrant dated June 15, 2006.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| FAVRILLE, INC. |
| | | |
| | | |
| By: | | /s/ Tamara A. Seymour |
Date: June 20, 2006 | | | Tamara A. Seymour |
| | | Chief Financial Officer |
3
INDEX TO EXHIBITS
99.1 Press release of the registrant dated June 15, 2006.
4
